

Special Issue

Latest Research in Post-COVID (Long COVID): Pathological and Treatment Studies of Sequelae and Complications

Message from the Guest Editor

The SARS-CoV-2 virus led to a worldwide outbreak of the disease. Current knowledge on SARS-CoV-2 acute infection has dramatically increased. However, healthcare systems and professionals are fighting against a “hidden” and underestimated consequence of the virus: the presence of long-lasting symptoms after acute infection. This condition has been called long COVID or post-COVID-19 syndrome. In fact, “long-haulers” is the term used to refer to subjects who have recovered from SARS-CoV-2 infection but have developed post-COVID symptoms. Increasing studies have supported the presence of more than 100 potential symptoms after the acute phase of infection. Although long COVID as a term was proposed in July 2020, a potential consensus on the definition was only reached by the WHO in December 2021. However, several gaps are still present in the research regarding the identification, timeframe, mechanisms, and treatment strategies for the management of post-COVID symptoms. We are pleased to invite you to submit to this Special Issue, “Latest Research in Post-COVID (Long COVID): Pathological and Treatment Studies of Sequelae and Complications”.

Guest Editor

Prof. Dr. César Fernández-de-las-Peñas

Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, 28922 Alcorcón, Madrid, Spain

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/134362

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).